Patent ID: 8633222

Claim:
A method for the treatment of one or more of pre-senile dementia, early onset Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, Lewy Body dementia, micro-infarct dementia, AIDS-related dementia, HIV-dementia, mild cognitive impairment, age-associated memory impairment, premature amnesic disorder, age-related cognitive disorders, substance-related cognitive disorders, cognitive disorders related to immunodeficiency syndrome, cognitive disorders associated with vascular disorders, schizophrenia, cognitive dysfunction in schizophrenia, attention deficit disorder, attention deficit hyperactivity disorder, attention deficiencies, or learning deficiencies comprising: administering to a patient in need thereof an effective amount of a vinylazacycloalkane compound of Formula (I): wherein: the wavy line represents E geometry about the double bond; X is CR 2 ; R 1 is hydrogen, C 1-6 -alkyl, halogen, —OR 4 , —NR 4 R 5 , or —SR 4 ; R 2 is hydrogen, C 1-6 -alkyl, aryl, aryl-C 1-6 -alkyl, heteroaryl, heteroaryl-C 1-6 -alkyl, heterocyclyl, heterocyclyl-C 1-6 -alkyl, cycloalkyl, polycycloalkyl, —OR 6 , —NR 6 R 7 , —SR 6 , —SOR 6 , or —SO 2 R 6 , wherein the C 1-6 -alkyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl groups may be substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, —R 8 , —OR 8 , —NR 8 R 9 , —CF 3 , —OCF 3 , —CN, —NO 2 , —SR 8 , —S(O)R 8 , —SO 2 R 8 , —O—SO 2 R 8 , —C(═O)NR 8 R 9 , —NR 8 C(═O)R 9 , —C(═O)OR 8 , —OC(═O)R 8 , —NHSO 2 R 8 , —SO 2 NR 8 R 9 , —C(S)NR 8 R 9 , and —NHC(S)R 8 ; R 3 is hydrogen or methyl; R 4 and R 5 are, independently, hydrogen or C 1-6 -alkyl; R 6 and R 7 are, independently, hydrogen, C 1-6 -alkyl, aryl, aryl-C 1-6 -alkyl, heteroaryl, heteroaryl-C 1-6 -alkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, or polycycloalkyl, wherein the C 1-6 -alkyl, cycloalkyl, heterocyclyl, heteroaryl and aryl groups can be substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, —R 8 , —NR 8 R 9 , —CF 3 , —CN, —NO 2 , —C 2 R 8 , —N 3 , —SO 2 CH 3 , —OR 8 , —SR 8 , —C(═O)NR 8 R 9 , —NR 8 C(═O)R 8 , —C(═O)R 8 , —C(═O)OR 8 , —(CH 2 ) q OR 8 , —OC(═O)R 8 , —OC(═O)NR 8 R 9 , and —NR 8 C(═O)OR 8 ; R 8 and R 9 are, independently, hydrogen, C 1-6 -alkyl, or an aromatic group-containing species, wherein the aromatic group-containing species can be substituted with one or more of C 1-6 -alkyl, halogen, or amino; or either R 6 and R 7 together or R 8 and R 9 together with the atoms to which they are attached form a 3- to 10-membered ring; m is 1, 2, 3, or 4; and n is 1, 2, or 3; or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.